[go: up one dir, main page]

ES2031151T3 - PROCEDURE FOR PREPARING DISPERSIBLE COLLOID SYSTEMS OF A SUBSTANCE, IN THE FORM OF MATRICIAL SPHERICAL PARTICLES. - Google Patents

PROCEDURE FOR PREPARING DISPERSIBLE COLLOID SYSTEMS OF A SUBSTANCE, IN THE FORM OF MATRICIAL SPHERICAL PARTICLES.

Info

Publication number
ES2031151T3
ES2031151T3 ES198787402997T ES87402997T ES2031151T3 ES 2031151 T3 ES2031151 T3 ES 2031151T3 ES 198787402997 T ES198787402997 T ES 198787402997T ES 87402997 T ES87402997 T ES 87402997T ES 2031151 T3 ES2031151 T3 ES 2031151T3
Authority
ES
Spain
Prior art keywords
substance
solvent
solvents
mixture
matricial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787402997T
Other languages
Spanish (es)
Other versions
ES2031151T5 (en
Inventor
Hatem Fessi
Jean-Philippe Devissaguet
Francis Puisieux
Curt Thies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9342497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2031151(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2031151T3 publication Critical patent/ES2031151T3/en
Publication of ES2031151T5 publication Critical patent/ES2031151T5/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/12—Powdering or granulating
    • C08J3/14—Powdering or granulating by precipitation from solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/849—Manufacture, treatment, or detection of nanostructure with scanning probe
    • Y10S977/86—Scanning probe structure
    • Y10S977/875—Scanning probe structure with tip detail
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Paper (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL PROCEDIMIENTO SEGUN LA INVENCION SE CARACTERIZA PORQUE: (1) SE PREPARA UNA FASE LIQUIDA CONSTITUIDA PRINCIPALMENTE POR UNA DISOLUCION DE LA SUSTANCIA EN UN DISOLVENTE O UNA MEZCLA DE DISOLVENTES, PUDIENDO AÑADIRSE UNO O VARIOS TENSIOACTIVOS; (2) SE PREPARA UNA SEGUNDA FASE LIQUIDA CONSTITUIDA PRICIPALMENTE POR UN NO DISOLVENTE O MEZCLA DE NO DISOLVENTES DE LA SUSTANCIA, AL QUE SE PUEDE AÑADIR UNO O VARIOS TENSIOACTIVOS, SIENDO EL DISOLVENTE O MEZCLA DE NO DISOLVENTES DE LA SUSTANCIA MISCIBLE EN TODAS PROPORCIONES CON EL DISOLVENTE O MECLA DE DISOLVENTES DE LA SUSTANCIA; (3) SE AÑADE, CON AGITACION MODERADA, UNA DE LAS FASES LIQUIDAS OBTENIDAS EN (1) O (2) A LA OTRA, PARA OBTENER UNA SUSPENSION COLOIDAL DE NANOPARTICULAS DE LA SUSTANCIA; Y (4) SI SE DESEA SE ELIMINA TODO O PARTE DEL DISOLVENTE O MEZCLA DE DISOLVENTES DE LA SUSTANCIA Y DEL NO DISOLVENTE O MEZCLA DE NO DISOLVENTES DE LA SUSTANCIA, PARA OBTENER UN SUSPENSION COLOIDAL DE CONCENTRACION DESEADA EN NANOPARTICULAS U OBTENER UNPOLVO DE NANOPARTICULAS. APLICACIONES: QUIMICA, BIOQUIMICA FARMACIA, MEDICINA.THE PROCEDURE ACCORDING TO THE INVENTION IS CHARACTERIZED BECAUSE: (1) A LIQUID PHASE IS PREPARED, CONSISTING MAINLY OF A SOLUTION OF THE SUBSTANCE IN A SOLVENT OR A MIXTURE OF SOLVENTS, MAY ADD ONE OR MULTIPLE SURFACTANTS; (2) A SECOND LIQUID PHASE IS PREPARED, CONSTITUTED PRICIPALLY BY A NON-SOLVENT OR MIXTURE OF NON-SOLVENTS OF THE SUBSTANCE, TO WHICH ONE OR MULTIPLE SURFACTANTS MAY BE ADDED, THE SOLVENT OR MIXTURE OF NON-SOLVENT BEING SOLVENT THE SOLVENT OR MECLA OF SOLVENTS OF THE SUBSTANCE; (3) ONE OF THE LIQUID PHASES OBTAINED IN (1) OR (2) IS ADDED, WITH MODERATE AGITATION, TO OBTAIN A COLLOIDAL SUSPENSION OF NANOPARTICLES OF THE SUBSTANCE; AND (4) IF DESIRED, ALL OR PART OF THE SOLVENT OR MIXTURE OF SOLVENTS OF THE SUBSTANCE AND OF THE NON-SOLVENT OR MIXTURE OF NON-SOLVENTS OF THE SUBSTANCE IS REMOVED, TO OBTAIN A DESIRABLE COLLOIDAL SUSPENSION FROM NANOPARENULAN UANPARPULULAS. APPLICATIONS: CHEMISTRY, BIOCHEMISTRY PHARMACY, MEDICINE.

ES87402997T 1986-12-31 1987-12-28 PROCEDURE FOR PREPARING DISPERSIBLE COLLOID SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES. Expired - Lifetime ES2031151T5 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8618446A FR2608988B1 (en) 1986-12-31 1986-12-31 PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES

Publications (2)

Publication Number Publication Date
ES2031151T3 true ES2031151T3 (en) 1992-12-01
ES2031151T5 ES2031151T5 (en) 1996-01-16

Family

ID=9342497

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87402997T Expired - Lifetime ES2031151T5 (en) 1986-12-31 1987-12-28 PROCEDURE FOR PREPARING DISPERSIBLE COLLOID SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES.

Country Status (9)

Country Link
US (1) US5118528A (en)
EP (1) EP0275796B2 (en)
JP (1) JP2739896B2 (en)
AT (1) ATE74024T1 (en)
CA (1) CA1292168C (en)
DE (1) DE3777796D1 (en)
ES (1) ES2031151T5 (en)
FR (1) FR2608988B1 (en)
GR (2) GR3004152T3 (en)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE84710T1 (en) * 1988-06-30 1993-02-15 Centre Nat Rech Scient PROCESSES FOR THE PRODUCTION OF COLLOIDAL DISPERSABLE PROTEIN SYSTEMS LIKE NANOPARTICLES.
FR2634376B1 (en) 1988-07-21 1992-04-17 Farmalyoc NOVEL SOLID AND POROUS UNIT FORM COMPRISING MICROPARTICLES AND / OR NANOPARTICLES, AS WELL AS ITS PREPARATION
JP2843857B2 (en) * 1988-10-05 1999-01-06 ファルマシア・アンド・アップジョン・カンパニー Finely divided solid crystalline powder via precipitation in antisolvent
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
JP2582186B2 (en) * 1989-05-04 1997-02-19 サウザン リサーチ インスティチュート Encapsulation method and its products
FR2659554B1 (en) * 1990-03-16 1994-09-30 Oreal COMPOSITION FOR THE COSMETIC AND / OR PHARMACEUTICAL TREATMENT OF THE TOP LAYERS OF THE EPIDERMIS BY TOPICAL APPLICATION TO THE SKIN AND PREPARATION METHOD THEREOF.
KR930006431B1 (en) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 Microcapsulation of drugs
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
FR2678178A1 (en) * 1991-06-28 1992-12-31 Rhone Poulenc Rorer Sa PROCESS FOR THE PREPARATION OF NANOPARTICLES.
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
ES2034891B1 (en) * 1991-08-08 1993-12-16 Cusi Lab CONTINUOUS ELABORATION PROCEDURE OF SCATTERED COLLOID SYSTEMS, IN THE FORM OF NANOCAPSULES OR NANOPARTICLES.
DE4140172C2 (en) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retard form for a drug containing ibuprofen
DE4140184C2 (en) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Acute form for a medicine containing flurbiprofen
DE4140179C2 (en) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Acute form for a drug containing ibuprofen
DE4140191C2 (en) * 1991-12-05 1998-02-19 Alfatec Pharma Gmbh Retard form for a drug containing indomethacin or acemetacin and its manufacture
DE4140185C2 (en) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Medicament containing a 2-arylpropionic acid derivative in nanosol form and its preparation
DE4140183C2 (en) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retard form for a medicine containing flurbiprofen
ATE137962T1 (en) * 1991-12-05 1996-06-15 Alfatec Pharma Gmbh PHARMACEUTICALLY APPLICABLE NANOSOL AND METHOD FOR THE PRODUCTION THEREOF
DE4140195C2 (en) * 1991-12-05 1994-10-27 Alfatec Pharma Gmbh Pharmaceutical nanosol and process for its manufacture
GB9300875D0 (en) * 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
AU695125B2 (en) * 1993-02-02 1998-08-06 Xoma Corporation Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant
US20070122465A1 (en) * 1993-02-22 2007-05-31 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
DE4329446A1 (en) * 1993-09-01 1995-03-02 Basf Ag Process for the production of finely divided color or active substance preparations
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
ES2078190B1 (en) * 1994-05-20 1996-08-01 Cusi Lab PROCEDURE FOR THE COATING OF GOTICLES OR PARTICLES OF NANOMETRIC SIZE.
US5932544A (en) 1994-05-31 1999-08-03 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) compositions
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
JP4484247B2 (en) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド Aerosol containing nanoparticle dispersion
TW493991B (en) * 1995-05-08 2002-07-11 Novartis Ag Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US5718922A (en) * 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
DE69526787T2 (en) * 1995-07-05 2002-12-05 European Community, Luxemburg/Luxembourg Biocompatible and biodegradable nanocapsules for the absorption and administration of protein pharmaceuticals
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US6391338B1 (en) 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
FR2742357B1 (en) * 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa STABILIZED AND FILTRABLE NANOPARTICLES UNDER STERILE CONDITIONS
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
IL133672A0 (en) * 1997-06-27 2001-04-30 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO1999033558A1 (en) * 1997-12-29 1999-07-08 Universite De Geneve Method for producing an aqueous colloidal dispersion of nanoparticles
GB9815271D0 (en) 1998-07-14 1998-09-09 Cambridge Display Tech Ltd Particles and devices comprising particles
DE19839515B4 (en) * 1998-08-29 2012-02-02 Nanohale Gmbh New pharmaceutical preparation containing colloidal polymer-drug associations, especially for mucosal drug administration
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
DE19856432A1 (en) 1998-12-08 2000-06-15 Basf Ag Nanoparticulate core-shell systems and their use in pharmaceutical and cosmetic preparations
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
DE19911058B4 (en) * 1999-03-12 2004-09-30 Biotec Asa Use of nanoscale water-soluble β- (1,3) -glucans
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
WO2001002087A1 (en) * 1999-07-06 2001-01-11 Universite De Geneve Laboratoire De Pharmacie Galenique Method for producing aqueous colloidal dispersions of nanoparticles
AU2001233174A1 (en) * 2000-01-31 2001-08-07 Engelhard Corporation Surfactant free topical compositions and method for rapid preparation thereof
DE10008305A1 (en) * 2000-02-23 2001-09-06 Henkel Kgaa Micro- and nano-capsules with cationic charges on surface are used in laundry and other detergents, skin cleansers, shampoos and skin and hair cosmetics
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
CA2309575A1 (en) * 2000-05-26 2001-11-26 James E. Guillet Internally cross-linked macromolecules
US20060177416A1 (en) * 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7998507B2 (en) 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
EP1341521B1 (en) * 2000-11-20 2009-01-07 Elan Pharma International Limited Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
IL156310A0 (en) * 2000-12-22 2004-01-04 Baxter Int Method for preparing submicron particle suspensions
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
CA2433361A1 (en) * 2000-12-29 2002-07-11 Sidney Pestka Controlled release systems for polymers
ES2178961B1 (en) * 2001-03-06 2004-07-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. MANUFACTURE OF NANOPARTICULES BASED ON THE COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE FOR THE ADMINISTRATION OF PHARMACES OF HYDROPHYLICAL NATURE, IN PARTICULAR OF PURIC BASES AND PYRIMIDINICS.
AU2002257116A1 (en) 2001-03-30 2002-10-15 Trustees Of Princeton University A process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
US7914755B2 (en) * 2001-04-12 2011-03-29 Eestor, Inc. Method of preparing ceramic powders using chelate precursors
JP4223390B2 (en) * 2001-06-05 2009-02-12 エラン・ファルマ・インターナショナル・リミテッド System and method for milling material
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
JP2004534811A (en) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク Pharmaceutical composition comprising a polymer and drug assembly
US20080305173A1 (en) * 2001-07-31 2008-12-11 Beuford Arlie Bogue Amorphous drug beads
WO2003011254A1 (en) * 2001-07-31 2003-02-13 Capricorn Pharma Inc. Amorphous drug beads
ES2287293T3 (en) * 2001-08-06 2007-12-16 Astrazeneca Ab WATERPROOF DISPERSION THAT INCLUDES STABLE NANOPARTICULES OF MEDIUM CHAIN TRIGLICERIDS (MCT) ACTIVE, INSOLUBLE IN WATER AND OF EXCIPIENT TYPE.
WO2003013683A1 (en) * 2001-08-08 2003-02-20 Brown University Research Foundation Methods for micronization of hydrophobic drugs
JP3728411B2 (en) * 2001-09-18 2005-12-21 ソニー株式会社 Method for producing magnetic particle, magnetic particle and magnetic material
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
US7048771B2 (en) * 2001-10-22 2006-05-23 University Of California Dyeing textiles using nanoparticles
ES2260488T3 (en) * 2001-11-07 2006-11-01 Basf Aktiengesellschaft SOLID FORMULATIONS AND DISPERSION FORMULATIONS FOR THE PROTECTION OF CROPS AND ITS USE IN AGRICULTURE.
CA2469718A1 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
JP2003210970A (en) * 2002-01-17 2003-07-29 Tokuyama Corp Method for producing colloidal fine particle slurry
US6720008B2 (en) 2002-01-22 2004-04-13 Pr Pharmaceuticals, Inc. Composition and method for the encapsulation of water-soluble molecules into nanoparticles
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
CA2475092C (en) * 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
ATE385777T1 (en) * 2002-03-20 2008-03-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF MITOGEN-ACTIVATED PROTEIN (MAP) KINASE INHIBITORS
EP1511467A1 (en) 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate polycosanol formulations and novel polycosanol combinations
DE10231757A1 (en) * 2002-07-13 2004-01-22 Creavis Gesellschaft Für Technologie Und Innovation Mbh Process for the preparation of a surfactant-free suspension on an aqueous basis of nanostructured, hydrophobic particles and their use
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
LT1585548T (en) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
EP1628641A2 (en) * 2003-05-19 2006-03-01 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
US9044381B2 (en) * 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
ES2232287B1 (en) * 2003-07-04 2006-11-01 Advanced In Vitro Cell Technologies, S.L. POLYOXYETHYLATE DERIVATIVES NANOPARTICLES.
AU2004263040B2 (en) * 2003-08-06 2010-03-11 Eisai R&D Management Co., Ltd. Process for producing drug ultramicroparticle and apparatus therefor
DE602004018150D1 (en) * 2003-08-08 2009-01-15 Elan Pharma Int Ltd NEW METAXALON COMPOSITIONS
WO2005020933A2 (en) 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
AU2004275764B2 (en) 2003-09-22 2010-01-14 Baxter Healthcare S.A. High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
DE10351004A1 (en) 2003-10-30 2005-05-25 Basf Ag Aqueous nanodispersion-forming formulations of active agents, especially plant protectants such as fungicides, comprise random copolymer of unsaturated sulfonic acid(s)
EP1688169A4 (en) * 2003-11-28 2008-10-01 Mitsubishi Chem Corp METHOD FOR PRODUCING FINE PARTICLES OF AN ORGANIC COMPOUND
EP1727520A2 (en) * 2003-12-09 2006-12-06 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
CN1913871A (en) * 2004-01-29 2007-02-14 巴克斯特国际公司 Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
WO2005077337A2 (en) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions prepared by use of self-stabilizing agents
IL160858A (en) * 2004-03-14 2015-09-24 Adama Makhteshim Ltd Nanoparticulate pesticidal composition and a process for its preparation
WO2005095950A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Method and device for evaluation of pharmaceutical compositions
ES2246695B1 (en) * 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. STIMULATING COMPOSITION OF THE IMMUNE RESPONSE THAT INCLUDES NANOPARTICLES BASED ON A COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE.
ES2246694B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. PEGILATED NANOPARTICLES.
WO2005108392A2 (en) * 2004-05-07 2005-11-17 Taro Pharmaceutical Industries Ltd. Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
US20080287456A1 (en) * 2004-05-28 2008-11-20 Imaginot Pty Ltd Oral Therapeutic Compound Delivery System
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
KR20070037444A (en) * 2004-06-15 2007-04-04 백스터 인터내셔널 인코포레이티드 In Vitro Application of Solid Particulate Therapeutics
US20060057215A1 (en) * 2004-09-15 2006-03-16 Raiche Adrian T Method for the production of nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
US7495052B2 (en) * 2004-09-15 2009-02-24 Bausch & Lomb Incorporated Method for the production of polymerized nanoparticles and microparticles by ternary agent concentration and temperature alteration induced immiscibility
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
DE102005025057B4 (en) 2005-05-30 2008-01-10 Gkss-Forschungszentrum Geesthacht Gmbh Process for producing nanoparticles using porous membranes
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
BRPI0612071A2 (en) * 2005-06-14 2010-10-19 Baxter Int pharmaceutical formulations to minimize drug interactions
BRPI0615292A8 (en) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc compositions and methods for preparing poorly soluble water drugs with increased stability
SI3311805T1 (en) * 2005-08-31 2020-07-31 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
AU2006293410B2 (en) * 2005-09-20 2012-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nanoparticles for targeted delivery of active agents
US20080220970A1 (en) * 2005-10-27 2008-09-11 Basf Se Agrochemical Nanoparticulate Active Ingredient Formulations
JP2009516003A (en) * 2005-11-15 2009-04-16 バクスター・インターナショナル・インコーポレイテッド Composition of a lipoxygenase inhibitor
US9757455B2 (en) 2005-11-28 2017-09-12 Johnson & Johnson Consumer Inc. Oral therapeutic compound delivery system
EP1954252B1 (en) * 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticles for use in immunogenic compositions
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
ES2776100T3 (en) 2006-03-31 2020-07-29 Massachusetts Inst Technology System for targeted delivery of therapeutic agents
US20080193518A1 (en) * 2006-04-28 2008-08-14 Schering Corporation Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US8853116B2 (en) 2006-08-02 2014-10-07 Eestor, Inc. Method of preparing ceramic powders
US7993611B2 (en) * 2006-08-02 2011-08-09 Eestor, Inc. Method of preparing ceramic powders using ammonium oxalate
US20090306339A1 (en) * 2006-09-19 2009-12-10 Van Boxtel Huibert Albertus Preparation of Fine Particles
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
WO2008080047A2 (en) * 2006-12-23 2008-07-03 Baxter International Inc. Magnetic separation of fine particles from compositions
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124639A2 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
EP2152274A4 (en) * 2007-05-07 2010-07-21 Questor Pharmaceuticals Inc Nasal administration of benzodiazepines
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US20080293814A1 (en) * 2007-05-22 2008-11-27 Deepak Tiwari Concentrate esmolol
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2009010837A2 (en) 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
EP2044934A1 (en) * 2007-10-01 2009-04-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Dispersion of poloxamer-protein particles, methods of manufacturing and uses thereof
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN AMINO-FUNCTIONALIZED METHACRYLATE COPOLYMER
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2229233B1 (en) * 2007-12-07 2019-10-09 XSpray Pharma AB (publ) Method for the production of particles
EP2085080A1 (en) * 2008-01-30 2009-08-05 LEK Pharmaceuticals D.D. Preparation of nanoparticles by using a vibrating nozzle device
BRPI0909780B1 (en) 2008-03-05 2022-05-03 Baxter International Inc Suspension containing a surface-modified particle, pharmaceutical composition comprising said suspension, method for enhancing cellular uptake of an active agent, use of surface-modified particles, and method of preparing a surface-modified particle
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
JP2011518885A (en) * 2008-04-28 2011-06-30 ノバルティス アーゲー Nanoparticles for use in pharmaceutical compositions
US20100015240A1 (en) * 2008-07-16 2010-01-21 Danielle Biggs Process for preparing microparticles containing bioactive peptides
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
WO2010042555A2 (en) 2008-10-06 2010-04-15 The Brigham And Women's Hospital, Inc. Particles with multiple functionalized surface domains
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
EP2385824A2 (en) 2009-01-06 2011-11-16 Pharmanova, Inc. Nanoparticle pharmaceutical formulations
EP3246048B1 (en) 2009-02-18 2024-04-03 Calm Water Therapeutics LLC Bi-functional co-polymer use for ophthalmic applications
US20100285316A1 (en) * 2009-02-27 2010-11-11 Eestor, Inc. Method of Preparing Ceramic Powders
CA2752696A1 (en) * 2009-02-27 2010-09-02 Eestor, Inc. Reaction tube and hydrothermal processing for the wet chemical co-precipitation of oxide powders
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
AU2010254180B2 (en) 2009-05-27 2015-08-27 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
MX357630B (en) 2009-05-27 2018-07-17 Selecta Biosciences Inc Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents.
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
US8815262B2 (en) 2010-01-29 2014-08-26 Fujifilm Corporation Pharmaceutical composition and preparation for oral administration
WO2011119262A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
US9192901B2 (en) * 2010-05-25 2015-11-24 Ucl Business Plc Co-current mixer, apparatus, reactor and method for precipitating nanoparticles
EA030813B1 (en) 2010-05-26 2018-10-31 Селекта Байосайенсиз, Инк Methods of generating an antibody immune response and enhancing local induction of immune cytokines when using synthetic nanocarriers coupled with adjuvants
EP2575988A1 (en) 2010-05-28 2013-04-10 Tetris Online, Inc. Interactive hybrid asynchronous computer game infrastructure
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012059936A1 (en) 2010-11-03 2012-05-10 Padma Venkitachalam Devarajan Pharmaceutical compositions for colloidal drug delivery
US8546521B2 (en) 2011-01-28 2013-10-01 Cerulean Pharma Inc. Method for fabricating nanoparticles
CN103796656A (en) 2011-06-14 2014-05-14 哈尔生物药投资有限责任公司 Administration of benzodiazepines
WO2013019648A1 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
AU2014212109B2 (en) 2013-02-01 2018-05-31 Glialogix, Inc. Compositions and methods for the treatment of neurodegenerative and other diseases
US9732068B1 (en) 2013-03-15 2017-08-15 GenSyn Technologies, Inc. System for crystalizing chemical compounds and methodologies for utilizing the same
WO2015157509A1 (en) * 2014-04-10 2015-10-15 The Trustees Of The University Of Pennsylvania Compositions and methods for treating opioid receptor associated diseases
WO2016183217A1 (en) 2015-05-11 2016-11-17 Yale University Functionalized polymeric particles for treatment of gliomas
WO2015172153A1 (en) 2014-05-09 2015-11-12 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
GB201412841D0 (en) 2014-07-18 2014-09-03 Univ Liverpool Particles
RU2688670C1 (en) * 2015-11-17 2019-05-22 Александр Александрович Кролевец Method for producing nanocapsules of ciprofloxacin hydrochloride in konjac gum
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
KR102590498B1 (en) * 2016-02-19 2023-10-19 삼성디스플레이 주식회사 Flexible display device, method for fabricating window member of the same, hard coating composition
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
US20190231704A1 (en) 2016-09-23 2019-08-01 Yale University Compositions for enhanced uptake by macrophages and methods of use thereof
TW201818933A (en) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 Compositions and methods for the treatment of neurodegenerative and other diseases
PL3548001T3 (en) * 2016-11-30 2022-07-11 Dukebox Sp. Z O.O. A method of manufacturing a solution of nanoparticles of acetylsalicylic acid or diosmin or drotaverine
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
RU2657767C1 (en) * 2017-08-07 2018-06-15 Александр Александрович Кролевец Method for producing nanocapsules of streptoticide in kappa-carrageenan
FR3081350B1 (en) * 2018-05-24 2020-08-28 Paris Sciences Lettres Quartier Latin COLLOIDAL PARTICLES HOMOGENEOUSLY FUNCTIONALIZED BY BIOMOLECULES
WO2020033951A1 (en) 2018-08-10 2020-02-13 Yale University Compositions and methods for embryonic gene editing in vitro
FR3106625B1 (en) 2020-01-27 2022-11-04 Safran Helicopter Engines Aircraft engine fuel system
FR3110427B1 (en) 2020-05-20 2023-07-14 Laboratoires Eriger Coupling terpene conjugate
CN112451483B (en) * 2020-12-14 2022-06-10 浙江圣兆药物科技股份有限公司 Preparation method of paliperidone palmitate suspension
IL315874A (en) 2022-03-30 2024-11-01 Evonik Operations Gmbh Formulations composed of cationic lipids and poly(lactic-co-glycolic acid) for the delivery of polynucleotides into cells
GB202307563D0 (en) 2023-05-19 2023-07-05 Univ King Abdullah Sci & Tech Methods and compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH201942A (en) * 1935-07-08 1938-12-31 A Dr Krause Georg Process for the production of brines respectively. Suspensions of organic substances.
DE738604C (en) * 1935-07-09 1943-08-23 Rudolf Degkwitz Dr Process for the production of hydrosols with a selectable shape and size of the colloidal particles
BE744162A (en) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd ENCAPSULATION PROCESS
US4585651A (en) * 1978-10-17 1986-04-29 Stolle Research & Development Corporation Active/passive immunization of the internal female reproductive organs
US4492720A (en) * 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
JPS61211342A (en) * 1985-03-15 1986-09-19 Asahi Chem Ind Co Ltd Manufacturing method of ultrafine polymer particles

Also Published As

Publication number Publication date
ES2031151T5 (en) 1996-01-16
CA1292168C (en) 1991-11-19
US5118528A (en) 1992-06-02
FR2608988B1 (en) 1991-01-11
JP2739896B2 (en) 1998-04-15
EP0275796A1 (en) 1988-07-27
EP0275796B1 (en) 1992-03-25
ATE74024T1 (en) 1992-04-15
GR3018122T3 (en) 1996-02-29
FR2608988A1 (en) 1988-07-01
GR3004152T3 (en) 1993-03-31
JPS63240936A (en) 1988-10-06
DE3777796D1 (en) 1992-04-30
EP0275796B2 (en) 1995-09-06

Similar Documents

Publication Publication Date Title
ES2031151T3 (en) PROCEDURE FOR PREPARING DISPERSIBLE COLLOID SYSTEMS OF A SUBSTANCE, IN THE FORM OF MATRICIAL SPHERICAL PARTICLES.
FR2608942B1 (en) PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOCAPSULES
ES2054052T3 (en) PROCEDURE FOR THE PREPARATION OF DISPERSIBLE COLLOID SYSTEMS OF A PROTEIN IN THE FORM OF NANOPARTICLES.
FR2692168B1 (en) Preparation and use of new dispersible colloidal systems based on cyclodextrin, in the form of nanospheres.
AU675788B2 (en) Process for preparing microspheres for the prolonged releaseof the LHRH hormone and its analogues, microspheres and formulations obtained
DE3364299D1 (en) Pulverized mixture of lipid and hydrophobic constituents, process for preparing them, hydrated lipid lamellar phases and process for preparing them, pharmaceutical or cosmetic compositions containing hydrated lamellar lipid phases
MX337149B (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof.
NL7809522A (en) PROCESS FOR PREPARING PHARMACEUTICAL, COSMETIC AND DIAGNOSTIC MATERIALS.
DE3382587D1 (en) INJECTABLE LONG-TERM MICROPARTICLE PREPARATION FOR ADMINISTRATION OF ANTI-INFLAMMATORY AGENTS.
DE3562555D1 (en) Galenical form for oral administration and its method of preparation by lyophilization of an oil-in-water emulsion
ES8707103A1 (en) METHOD FOR PREPARING AN EXTEMPORANEOUS HOMOGENOUS MICROCAPSULES SUSPENSION
ATE325605T1 (en) STABILIZED PARTICLES IN LIQUID FORMULATIONS
ATE77401T1 (en) THIXOTROPIC PREPARATIONS, USE OF POLYCARBONICAMIDES IN THEIR PREPARATION AND SILICON DIOXIDE COATED WITH POLYCARBONICAMIDES.
HUT54885A (en) Process for producing liofilized pharmaceutical compositions containing active components
NO960232L (en) Method for coating droplets or nanoparticles
FR2806005B1 (en) PROCESS FOR THE PREPARATION OF COLLOIDAL PARTICLES IN THE FORM OF NANOCAPSULES
EP0283573B1 (en) Anhydrous administration formulation of low-molecular weight alkali huminates
Edman Pharmaceutical formulations—Suspensions and solutions
PL308838A1 (en) Pharmaceutical preparation containing cefixim as its active substance and method of stabilising such preparations
EP2272504A3 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB1468815A (en) Pharmaceutical compositions
MARUYAMA Interaction of myosin and F-actin in solution
RU1813449C (en) Method for producing oil suspension of interferon
ITMI961236A1 (en) METHOD FOR THE PRODUCTION OF STABLE AQUEOUS SUSPENSIONS, USEFUL IN PHARMACEUTICAL COMPOSITIONS
CN1284329A (en) Oil dispersed preparation of oil insoluble medicine